The current status of orphan drug development in Europe and the US
Authors:
- 1 January 2014
- journal article
- review article
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Intractable & Rare Diseases Research
- Vol. 3 (1) , 1-7
Abstract
Orphan drug legislation has been introduced in a number of countries in order to stimulate the development of treatments for rare diseases by introducing commercial incentives for companies wishing to undertake that development. In order to navigate the maze of regulatory regulations and procedures so that companies can make proper use of the orphan drug incentives, specialist knowledge is required. This article will review the current status of orphan drug development in the EU and the US, explain the incentives and procedures, and touch on the role of patient organisations in the process.Keywords
This publication has 2 references indexed in Scilit:
- Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?Orphanet Journal of Rare Diseases, 2012
- Adopting Orphan Drugs — Two Dozen Years of Treating Rare DiseasesNew England Journal of Medicine, 2006